Table 4.

Effect of acute i.v. injection of vehicle, alosetron and tegaserod on MAP and HR of non-fasted rats during a prolonged period of time (140 min)

Treatment and recording period	MAP (mmHg)	HR (beats·min−1)
Vehicle (10% NMP) 25–10 min pre	81.6 ± 5.51	362 ± 19.1
Vehicle (10% NMP) 5–20 min post	80.1 ± 4.85	363 ± 20.6
Vehicle (10% NMP) 65–80 min post	74.0 ± 5.27	353 ± 18.9
Vehicle (10% NMP) 125–140 min post	69.6 ± 5.61**	342 ± 17.9**
Alosetron (0.03 mg·kg−1) 25–10 min pre	89.8 ± 3.79	355 ± 39.2
Alosetron (0.03 mg·kg−1) 5–20 min post	92.8 ± 3.54	356 ± 40.6
Alosetron (0.03 mg·kg−1) 65–80 min post	90.3 ± 4.65	363 ± 42.1
Alosetron (0.03 mg·kg−1) 125–140 min post	80.9 ± 7.33	372 ± 49.1
Tegaserod (1 mg·kg−1) 25–10 min pre	87.7 ± 5.60	354 ± 13.4
Tegaserod (1 mg·kg−1) 5–20 min post	83.0 ± 5.64	333 ± 11.9
Tegaserod (1 mg·kg−1) 65–80 min post	82.3 ± 4.08	347 ± 15.4
Tegaserod (1 mg·kg−1) 125–140 min post	74.3 ± 3.78	352 ± 14.2

The experimental parameters were recorded and averaged during the pre-injection and post-injection periods as indicated. Means ± SEM, n= 7–8.

^**P < 0.01 versus pre-injection (one-way anova for repeated measures followed by the Bonferroni test).

HR, heart rate; MAP, mean arterial blood pressure; NMP, 1-methyl-2-pyrrolidone.